Safety and Pharmacology of CIGB-300 in cervical cancer (CERVIFARM-300 Study)

General information

Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.

Scientific title:

Safety and pharmacological evaluation of the intratumoral CIGB-300 application to patients with stage IB2-II cervical cancer

Secondary indentifying numbers:

IG/CIGB300I/CC/0701

Issuing authority of the secondary identifying numbers:

Center for Genetic Engineering and Biotechnology (CIGB)

Source(s) of monetary or material support:

HeberBiotec S.A. Chemo Group

Authorization for beginning

Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.

Regulatory instance to authorize the initiation of the study:

Center for State Control of the Quality of Drugs(CECMED)

Authorization date :

20/02/2008

Reference number:

05.018.07.B

Principal investigator

Section to complete information about Email address, telephone number and postal address of the Principal Investigator.

First name:

Jorge Luis Soriano García, MD, 2nd Degree Specialist in Oncology.

Last name:

Not entered

Affiliation:

Not entered

Postal address:

Not entered

City:

Not entered

País:

Not entered

Zip Code:

Not entered

Email address:

email@not.entered

Clinical sites to participate

Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.

Countries of recruitment:

Cuba

Clinical sites:

- Havana, Gineco-Obstetrician Hospital “Clodomira Acosta Ferrales”, Margarita Solares Asteasuainzarra, MD, 2nd Degree Specialist in Obstetrics and Gynecology - Havana, Central Clinic “Cira García”, Alba Vilaida Vaillant Baralt, MD, 2nd Degree Specialist in Imagenology

Research ethics committees:

- University Hospital “Hermanos Ameijeiras”, Havana, February 4, 2008. - Gineco-Obstetrician Hospital “Clodomira Acosta Ferrales”, Havana, July 24, 2008. - Central Clinic “Cira García”, Havana, July 8, 2008.

Recruitment status

Section to complete information about the recruitment status and the date of first enrolment subject

Recruitment status:

Complete

Date of first enrollment:

20/03/2008

Health condition and Intervention

Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).

Health condition(s) or Problem(s) studied:

Cervical epidermoid carcinoma, stage IB2-II.

Intervention(s):

Study group (CIGB-300, 35mg). Doses of 35 mg resuspended in 2 ml of water for injection, applied by intratumor route once per day, during 5 days. Conventional chemo-radiotherapy will start 25- 35 days after CIGB-300 treatment according to specific international guidelines for this pathology. The regimen consists in cisplatin 40 mg/m2, once per week, during 6 weeks, concomitant to 5040 cGy of external beam radiotherapy given in 28 fractions. This will be followed by 2600 cGy of intracavitary radiotherapy given in 4 high dose fractions (650 cGy/day) over 2 weeks. Study group (CIGB-300, 70mg). Doses of 70 mg resuspended in 2 ml of water for injection, applied by intratumor route once per day, during 5 days. Conventional chemo-radiotherapy will start 25- 35 days after CIGB-300 treatment according to specific international guidelines for this pathology. The regimen consists in cisplatin 40 mg/m2, once per week, during 6 weeks, concomitant to 5040 cGy of external beam radiotherapy given in 28 fractions. This will be followed by 2600 cGy of intracavitary radiotherapy given in 4 high dose fractions (650 cGy/day) over 2 weeks. Study group (CIGB-300, 245mg). Doses of 245 mg resuspended in 2 ml of water for injection, applied by intratumor route once per day, during 5 days. Conventional chemo-radiotherapy will start 25- 35 days after CIGB-300 treatment according to specific international guidelines for this pathology. The regimen consists in cisplatin 40 mg/m2, once per week, during 6 weeks, concomitant to 5040 cGy of external beam radiotherapy given in 28 fractions. This will be followed by 2600 cGy of intracavitary radiotherapy given in 4 high dose fractions (650 cGy/day) over 2 weeks. Study group (CIGB-300, 490mg). Doses of 490 mg resuspended in 2 ml of water for injection, applied by intratumor route once per day, during 5 days. Conventional chemo-radiotherapy will start 25- 35 days after CIGB-300 treatment according to specific international guidelines for this pathology. The regimen consists in cisplatin 40 mg/m2, once per week, during 6 weeks, concomitant to 5040 cGy of external beam radiotherapy given in 28 fractions. This will be followed by 2600 cGy of intracavitary radiotherapy given in 4 high dose fractions (650 cGy/day) over 2 weeks.

Outcomes and Timepoint

Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.

Primary outcome(s):

Biodistribution and Pharmacokinetics Biodistribution (Body gammagraphy. Distribution of the radiolabeled peptide in tumor and main source organs). Measuring time: 10 min, 1h, 2h, 4h, 8h, 12h, 16h, 24h, 36h and 48h after the first administration. Pharmacokinetic studies in serum, whole blood and urine (measurement of activity, and quantification of CIGB-300 serum by ELISA and HPLC). Measuring time: Immediately, 5 min, 15 min, 30 min, 1h, 2h, 4h, 8h, 12h, 16h, 24h, 36h and 48h after the first dose. The urine will be collected at intervals during this sampling period to determine the excreted magnitude and renal clearance. Safety variables: Presence of severe adverse events (Yes, No). Measuring time: until 24 hours after each administration. Presence of clinical Adverse Events (AE). Measuring time: until 24 hours after each administration. Then, patients will be followed during and at 3, 6, 9, and 12 months after chemo-radiotherapy. - Appearance of AE (Yes, No) - Type of AE (name of the AE) - Duration of AE (time from appearance to end of the event) - Intensity of AE (mild, moderate, severe) - Relation of causality (remote, possible, probable, very probable) - Result of AE (recuperate, improvement, persist or sequels) - Attitude concerning the studied treatment (without changes, dose modification, temporal or definitive treatment discontinuation). Vital signs (body temperature in Celsius degrees, heart rate in beats per minute, blood pressure in mmHg and respiratory rate in breaths per minute). Measuring time: before each dose, at 30min, 1h, 1h, 2h, 3h, 4h, 12h and 24h after each dose. Laboratory tests (complete blood count, glucemy, creatinine, transaminases). Measuring time: At baseline, and 21 days after treatment. Later weekly during chemo-radiotherapy and each three months during a one-year follow-up. Histamine plasmatic levels ( ELISA techniques). Measuring time: At baseline, 15min and 24h after the first dose; and at any other moment if a possible histamine release was suspected.

Key secondary outcomes:

Therapeutic response: Clinical colposcopic evaluation (Size of the tumoral lesion in diameters and area of the tumor surface captured by digital picture and measured using MADIP software). Measuring time: At baseline and 21 days after treatment. Later each three months during a one-year follow-up after chemo-radiotherapy. Imagenological evaluation (Tumor size using abdominal and transvaginal ultrasonography, CT scans, MRI, according to the evaluation criteria for solid tumors-RECIST). Measuring time: At baseline and 21 days after treatment. Later each three months during a one-year follow-up after chemo-radiotherapy.

Selection criterias

Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.

Gender:

Female

Minimum age:

18 years

Maximum age:

75 years

Inclusion criteria:

1. Clinical, imagenological and histological diagnosis of stage IB-II epidermoid cervical cancer. 2. Age between 18-75 years, both included. 3. Written informed consent by the patient. 4. Clinical laboratory parameters within normal limits. 5. General health index from 0 to 2, according to WHO classification. 6. Life expectation of more than 1 year.

Exclusion criteria:

1. To have received surgical, ablative or immunomodulatory treatment during the 30 days before inclusion. 2. Body Mass Index lower than 19 or greater than 30. 3. Pregnancy or nursing. 4. Decompensate chronic disease (arterial hypertension, diabetes mellitus, chronic renal disease, cardiac insufficiency,hyperthyroidism, malignant neoplasia, epilepsy, severe mental depression). 5. Patients with previous diagnosis of coagulation dysfunctions and other decompensate chronic hematopahies (hemophilia, leukemia, among other). 6. Clinical laboratory values outside their normal ranges before the treatment. 7. Referred Immunosuppressor disease and current ingestion of immunosuppressor / immunomodulating drugs (including steroids) 30 days previous the study. 8. Autoimmune disorders (Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Type 1 Diabetes Mellitus, etc.) and severe allergic antecedents such as Urticaria, Dermatitis, or Bronchitis and persistent Bronchial Asthma. 9. Febrile illness (temperature >37.8°C) at the moment or 24 hours before administration of the product or acute infectious disease suspected by clinical examination. 10. Diseases that compromise the state of the patient's conscience or their possibility to give their informed consent or to collaborate in the trial. 11. Tumoral extensive necrosis that prevent the application of the product as indicate the protocol. 12. To be included in another clinical trial.

Type of population:

Adults

Type of participant:

Patients

Study design

Section to complete information about the characteristics of the study design.

Type study:

Interventional

Purpose:

Treatment

Allocation:

Non-randomized controlled trial

Masking:

Open

Control group:

Uncontrolled

Study design:

Other

Other design:

Sequential dose escalation

Phase:

1

Target sample size:

24 (6 patients per group)

Contact for public queries

Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status

First Name:

Idania Idrian Lidia

Last Name:

Baladrón-Castrillo, MD García-García, MSc González-Méndez, MD

Affiliation:

Center for Genetic Engineering and Biotechnology (CIGB)

Postal Address:

Clinical Investigation Department, Ave. 134 between 23 and 25, Cubanacán, Playa.

City:

Havana

País:

Cuba

Zip Code:

P.O. Box 6332

Telephone:

+53 (7) 2087377; 2087379; 2087465 ext 108.

Email :

idania.baladron@cigb.edu.cu

Contact for scientific queries

Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.

First Name:

Idania Idrian Lidia

Last Name:

Baladrón-Castrillo, MD García-García, MSc González-Méndez, MD

Affiliation:

Center for Genetic Engineering and Biotechnology (CIGB)

Postal Address:

Clinical Investigation Department, Ave. 134 between 23 and 25, Cubanacán, Playa.

City:

Havana

País:

Cuba

Zip Code:

P.O. Box 6332

Telephone:

+53 (7) 2087377; 2087379; 2087465 ext 108.

Email :

idania.baladron@cigb.edu.cu

Registration and Update

Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).

Primary registry:

RPCEC

Unique ID number:

RPCEC00000141

Date of Registration in Primary Registry:

2013-01-18

Record Verification Date:

2013-01-08 19:00

Link to the spanish version:

Click here

Versión para impresión

Ensayos Registrados

Proceso de Registro

Safety and Pharmacology of CIGB-300 in cervical cancer (CERVIFARM-300 Study)

Acerca del RPCEC

Recursos útiles